Goofice (elobixibat) / Ferring, Eisai, Mochida, Ipsen - LARVOL DELTA

Bali Chronic Constipation Roundtable Report: Chronic Constipation Management in Asia. (PubMed, J Neurogastroenterol Motil) - "First line therapies such as dietary-fiber optimization and osmotic laxatives are widely available, but newer pharmacotherapies (prucalopride, linaclotide, lubiprostone, and elobixibat) remain costly and unevenly accessible. The Bali Chronic Constipation Roundtable highlighted Asia's need for region specific diagnostics and management. Addressing diagnostic and treatment gaps will improve outcomes, while ongoing researcher clinician policy collaboration must standardize guidelines, advance research, and ensure equitable care across Asia."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Cost-utility analysis of treatment strategies for chronic constipation in Japan. (PubMed, J Gastroenterol) - "The lubiprostone-elobixibat-PEG formulation strategy showed the most favorable cost-effectiveness profile. In addition, novel treatment options, including lubiprostone, linaclotide, elobixibat, and PEG formulation, were found to be cost-effective compared to MgO. Further research is warranted to confirm these findings and support their application in clinical practice."

HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Socioeconomic value of treatments for chronic idiopathic constipation in Japan. (PubMed, BMC Gastroenterol) - "Considering CIC-related medical costs, QoL, productivity loss, and caregiver burden, elobixibat 10 mg is associated with better QoL and lower costs than linaclotide 0.5 mg and lubiprostone 48 μg."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Laxative logic: when lifestyle is not enough. (PubMed, Curr Opin Gastroenterol) - "Patients with constipation now have access to a wide range of medications, from over-the-counter osmotic and stimulant agents to prescription laxative combination strategies. This breadth allows clinicians to tailor therapy to diverse pathophysiology and symptom profiles. Yet despite this choice, real-world adherence remains poor and many patients are dissatisfied, reflecting the complexity of treating constipation and frequent mismatches between therapy and patients' most bothersome symptoms. Management should emphasize careful symptom assessment, shared decision-making, and clear expectation setting, while leveraging the available armamentarium."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Carrier cross-reactivities of the bile acid reabsorption inhibitors elobixibat, linerixibat, maralixibat, and odevixibat. (PubMed, J Lipid Res) - "In contrast, this mutation had no significant effect on the ASBT inhibition by elobixibat, maralixibat, and odevixibat, indicating distinct binding sites. In conclusion, the analyzed BARIs revealed carrier cross-reactivities with NTCP, SOAT, and members of the OATP family, but behaved differently regarding their time-dependent inhibition and potential inhibitor binding sites."

Journal • Hepatitis B • Infectious Disease • Inflammation • SLCO2B1

Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation. (PubMed, JGH Open) - "Elobixibat increases the total fecal bile acid concentration of CC patients, which results in shortened colonic transit time. Trial Registration: JRCT ID: jRCTs061200030; https://rctportal.niph.go.jp/en/detail?trial_id=jRCTs061200030."

Clinical • Journal • Colorectal Cancer • Constipation • Gastroenterology • Gastrointestinal Disorder

Efficacy of elobixibat for elderly patients with chronic constipation in a clinic. (PubMed, World J Gastrointest Pharmacol Ther) - "Elobixibat is effective in improving bowel movement status in patients with chronic constipation. No significant differences were found in the improvement of bowel movement status or the incidence of adverse events between patients with chronic constipation aged < 65 years and ≥ 65 years, suggesting that the drug may be safely used in elderly patients."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison of the Effectiveness of Magnesium Oxide and Elobixibat on Improving Rectal Sensitivity and Colonic Transit Time in Patients With Chronic Constipation: An Observational Study. (PubMed, Neurogastroenterol Motil) - "EXB demonstrated significantly greater improvements of LODD, rectal sensation, and CTT compared to MgO."

Journal • Observational data • Constipation • Gastroenterology • Gastrointestinal Disorder

ANALYSES OF THE SOCIOECONOMIC VALUES OF TREATMENTS FOR CHRONIC CONSTIPATION IN JAPAN (DDW 2025) - "Methods Using data from clinical trials of Lubiprostone, Linaclotide, and Elobixibat conducted in Japan, changes in the number of spontaneous bowel movements (SBM) were synthesized using network meta-analysis (NMA), with placebo results set at zero for comparison. Sensitivity Analysis: The results were sensitive to the effectiveness of Elobixibat, but the trend remained consistent with the base case analysis for the other costs. Conclusions When selecting constipation treatment drugs, it is essential to consider not only their efficacy and cost but also their potential to reduce the socioeconomic burden associated with chronic constipation."

Constipation • Gastroenterology • Gastrointestinal Disorder

A MULTICENTER DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ELOBIXIBAT IN TREATING PATIENTS WITH CHRONIC CONSTIPATION (DDW 2025) - P3 | No abstract available

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder

Characterization of intestinal transporters in human ileal spheroid-derived differentiated cells for the prediction of intestinal drug absorption. (PubMed, Drug Metab Dispos) - "Proximal jejunal and terminal ileal spheroid-derived differentiated cell monolayers showed H+- and Na+-coupled uptake of methotrexate and [3H]-taurocholic acid, respectively. The functional expression of CYP3A, CYP2C9, UGT1A, P-glycoprotein, and breast cancer resistance protein (BCRP) was confirmed based on the formation of metabolites (1'-hydroxy midazolam, 4'-hydroxy diclofenac, raloxifene-4'-glucuronide, and raloxifene-6-glucuronide) and the efflux ratio of typical substrates (digoxin, sulfasalazine, rosuvastatin, dantrolene, and furosemide). Terminal ileum-derived differentiated cell monolayers showed extensive taurocholic acid-d5 transport in the apical-to-basal direction, which was markedly inhibited by the ASBT inhibitor elobixibat...To date, there is no in vitro model that can reproduce regional differences in the transporter-mediated transport of nutrients and drugs in the intestine. This study successfully demonstrated that the functional..."

Journal • Breast Cancer • Oncology • Solid Tumor • ABCG2 • CYP2C9

Decline of Persistent Jaundice in a Patient With Autoimmune Hepatitis and Vanishing Bile Duct Syndrome Treated With Elobixibat for Constipation. (PubMed, Cureus) - "Standard treatment, including methylprednisolone pulse therapy, prednisolone, azathioprine, bezafibrate, and ursodeoxycholic acid, failed to resolve jaundice. The observed efficacy of elobixibat suggests that it may be a valuable adjunctive therapy for severe cholestasis. Further research is warranted to clarify its therapeutic potential and underlying mechanisms in similar cases."

Journal • Autoimmune Hepatitis • Cholestasis • Constipation • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation • Primary Biliary Cholangitis

A novel ultra-sensitive LC-MS/MS method for determination of elobixibat in human plasma; Application to a bioequivalence study on healthy volunteers. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "Full bioanalytical validation as per FDA guidance was done over a range of 20.0-1500.0 pg/mL. The proposed method was successfully exploited for determination of elobixibat in human plasma samples and extended to estimate the pharmacokinetic parameters after administration of a single oral dose of 5 mg elobixibat tablet to thirty healthy volunteers."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: A final analysis report. (PubMed, SAGE Open Med) - "Most patients reported satisfaction from week 2 onward (6.0%, 66.9%, 78.6%, and 90.4% at baseline, weeks 2, 4, and 52, respectively). This study confirmed the long-term safety and efficacy of elobixibat in patients with chronic constipation, including many elderly ones, in routine clinical practice."

Journal • P4 data • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Efficacy and safety of elobixibat in patients with chronic constipation-A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India. (PubMed, Indian J Gastroenterol) - "Elobixibat was well tolerated and improved bowel movement frequency within two weeks of treatment in Indian patient population with chronic constipation."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Exploring the key structural attributes and chemico-biological interactions of pyridinone-based SARS-CoV-2 3CLpro inhibitors through validated structure-based drug design strategies. (PubMed, Heliyon) - "The presence of hydrophobic aromatic features as well as hydrophobic contacts at the S1 and S4 pockets were also found to have a key contribution to the SARS-CoV-2 3CLpro inhibition. Moreover, the screened drug candidate Elobixibat from the structure-based virtual screening also explored promising results as evidenced in MD simulation study and thus, can be a promising drug candidate that can be repurposed to assist in the development of effective anti-SARS-CoV-2 therapy."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Structure-Activity Relationships and Target Selectivity of Phenylsulfonylamino-Benzanilide Inhibitors Based on S1647 at the SLC10 Carriers ASBT, NTCP, and SOAT. (PubMed, J Med Chem) - "The ASBT inhibitors odevixibat, maralixibat, and elobixibat are used to treat intrahepatic cholestasis, cholestatic pruritus, and obstipation. The peptide drug bulevirtide blocks binding of the hepatitis B and D viruses to NTCP and thereby inhibits the virus's entry into hepatocytes...The present study aimed to comparatively analyze a set of newly synthesized and commercially available S1647 derivatives for their transport inhibition against ASBT, NTCP, and SOAT. Structure-activity relationships were systematically analyzed regarding potency and target specificity to elucidate whether this compound class is worth being further developed in preclinical studies for pharmacological ASBT, NTCP, and/or SOAT inhibition."

Journal • Breast Cancer • Cholestasis • Dermatology • Hepatitis B • Hepatology • Infectious Disease • Oncology • Pruritus • Solid Tumor

COMPARISON OF THE EFFICACY AND TOLERABILITY OF ELOBIXIBAT PLUS SODIUM PICOSULFATE WITH MAGNESIUM CITRATE AND SPLIT-DOSE 2-L POLYETHYLENE GLYCOL WITH ASCORBIC ACID FOR BOWEL PREPARATION BEFORE OUTPATIENT COLONOSCOPY: RESULTS OF MULTICENTER, RANDOMIZED, CONTROLLED TRIAL (UEGW 2024) - "A new regimen of elobixibat plus sodium picosulfate with magnesium citrate was non-inferior in bowel cleansing and superior in patient’s acceptability compared to split-dose 2-L polyethylene glycol with ascorbic acid."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Efficacy and safety of elobixibat in combination with or switched from conventional treatments of chronic constipation: A retrospective observational study. (PubMed, JGH Open) - "Elobixibat was effective in patients who were refractory to other laxatives, irrespective of previous therapy or patient characteristics. Elobixibat may contribute to resolving polypharmacy with single mode of action laxatives."

Combination therapy • Journal • Observational data • Retrospective data • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain

Usefulness of Elobixibat in Patients With Chronic Constipation After Cholecystectomy. (PubMed, Cureus) - "Elobixibat is useful in improving the bowel movements of patients with chronic constipation. No significant difference was noted in the improvement of bowel movements due to cholecystectomy. It was suggested that even post-cholecystectomy patients could obtain therapeutic effects similar to patients with gallbladders."

Journal • Constipation • Gastroenterology • Gastrointestinal Disorder

Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen (clinicaltrials.gov) - P=N/A | N=360 | Recruiting | Sponsor: Rajavithi Hospital | Not yet recruiting ➔ Recruiting

Enrollment open

Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen (clinicaltrials.gov) - P=N/A | N=360 | Not yet recruiting | Sponsor: Rajavithi Hospital

New trial

ELOBIXIBAT, A BILE ACID TRANSPORTER INHIBITOR, SIGNIFICANTLY IMPROVES STOOL AND/OR GAS DISTRIBUTION THROUGH TOTAL FECAL BILE ACIDS IN ELDERLY PATIENTS WITH CHRONIC CONSTIPATION: A RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (DDW 2024) - "Elobixibat significantly improved S/G distribution in patients with CC. The effect was correlated with changes in total fecal BAs."

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder

Open-Label, Single-Center, Single-Arm Study Evaluating the Efficacy and Safety of Elobixibat for Chronic Constipation in Patients With Heart Failure. (PubMed, Circ Rep) - "Serious adverse events were not observed. Elobixibat reduced the degree of straining during defecation, and improved the lipid profile in HF patients with chronic constipation."

Journal • Cardiovascular • Congestive Heart Failure • Constipation • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Heart Failure

Study of A3309 in Patients With Dyslipidemia (clinicaltrials.gov) - P2 | N=36 | Completed | Sponsor: Albireo | Phase classification: P2a ➔ P2

Phase classification • Dyslipidemia • Metabolic Disorders